大鼠中线剖腹手术控制可逆性内脏动脉缺血、静脉充血和联合灌注不良
2024年7月5日
1K 次观看
本文介绍了大鼠模型中受控、可逆性内脏器官灌注不良的标准化程序。目的是以高度的方法学确定性和控制性诱导这些灌注不良状态，同时保持技术简单性和容错能力。
我们的研究范围是生理和非灌注器官和组织的光谱表征。使用高光谱成像，我们希望能够可靠地识别和区分不同组织中的非灌注状态，并将这项技术确立为医学中的新诊断支柱，以缩小现有的诊断差距。当前非灌注器官光谱表征的实验挑战首先是缺乏标准化诱导不同非灌注状态的实验方案，以及可逆性的目标。
我们的结果为科学研究问题铺平了道路，这些问题涉及系统研究内脏灌注不良对生物分子、光谱和医学以及手术水平的影响，并有机会获得高时间分辨率以及灌注不良状态的可逆性。
概览
本文介绍了一种在大鼠模型中诱导可控、可逆的内脏器官供血不良的标准化程序。该方法旨在确保高度准确性和控制，同时保持技术简单性。
关键研究组成部分
科学领域
- 神经科学
- 生理学
- 医学影像
背景
- 供血不良状态可能显著影响器官功能。
- 目前用于诊断供血不良的方法有限。
- 高光谱成像为识别供血不良提供了潜在解决方案。
- 缺乏诱导供血不良的标准化协议。
研究目的
- 开发一种在大鼠模型中诱导供血不良的可靠方法。
- 利用高光谱成像来表征供血不良的器官。
- 建立一种新的诊断方法来识别供血不良状态。
使用的方法
- 通过外科技术在大鼠模型中诱导供血不良。
- 使用动脉瘤微血管夹进行可控的供血不良。
- 使用高光谱成像来评估氧合和灌注。
- 测量各个内脏器官的生理参数。
主要结果
- 使用高光谱成像验证了四种不同的供血不良状态。
- 在供血不良期间观察到显著的氧合和灌注减少。
- 氧饱和度值显著变化，表明存在缺血条件。
- 该研究为进一步研究内脏供血不良奠定了基础。
结论
- 标准化程序允许重复进行供血不良研究。
- 高光谱成像可以有效地区分供血不良状态。
- 这项研究为医学中改进诊断方法开辟了途径。
常见问题
什么是供血不良？
供血不良指的是器官或组织的血流不足，可能导致缺血性损伤。
高光谱成像是如何工作的？
高光谱成像捕获物体的广谱光，允许对其成分和状态进行详细分析。
这项研究的影响是什么？
这项研究可能会导致更好的诊断工具，用于在临床环境中识别和治疗供血不良。
为什么在供血不良研究中可逆性很重要？
可逆性允许研究人员研究供血不良的影响和恢复，为器官恢复力和治疗策略提供洞察。
这项研究研究了哪些器官？
该研究集中在几个内脏器官，包括胃和肝脏，以评估它们对供血不良的反应。
使用了哪些外科技术？
该研究采用开腹术和特定的夹持技术来在大鼠模型中诱导和逆转供血不良。
这项研究如何有利于未来的研究？
它为研究内脏供血不良提供了方法学框架，为该领域的进一步研究铺平了道路。
Executive Industry Relevance
Controlled, reversible induction of visceral malperfusion in rat models enables rigorous hypothesis testing for tissue perfusion mechanisms and imaging biomarker validation. This model addresses a critical gap in preclinical research by providing standardized, reproducible conditions for evaluating diagnostic modalities and therapeutic interventions targeting ischemia and congestion. The approach supports predictive confidence at the discovery-to-preclinical inflection point for vascular and tissue-targeted portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of arterial ischemia, venous congestion, and combined malperfusion in a controlled in vivo system.
- Supports functional target validation for vascular and tissue-protection pathways.
- Facilitates biological de-risking by isolating specific perfusion deficits and their molecular consequences.
- Provides a platform for evaluating the impact of candidate interventions on defined malperfusion states.
Screening & Assay Development
- Establishes validated, reproducible malperfusion states for downstream imaging and biomarker assay development.
- Enables quantitative measurement of oxygenation and perfusion indices across multiple organs using hyperspectral imaging.
- Supports standardization of imaging readouts for objective comparison of candidate diagnostics or therapeutics.
- Prepares biological systems for scalable screening of compounds or imaging agents targeting perfusion deficits.
Translational & Preclinical Research
- Aligns preclinical models with disease-relevant malperfusion mechanisms observed in clinical settings.
- Enables translational biomarker validation by correlating imaging outputs with defined physiological states.
- Supports risk-adjusted advancement of candidates by providing robust, reversible endpoints for efficacy and safety assessment.
- Facilitates continuity from discovery through preclinical validation for vascular and tissue-protection programs.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum by enabling hypothesis-driven testing, quantitative imaging, and translational biomarker alignment for vascular and tissue-targeted R&D.
- Discovery Biology: Provides a platform for isolating and testing specific malperfusion hypotheses in vivo.
- Screening: Delivers reproducible, quantitative imaging outputs for assay development and compound evaluation.
- Analytics: Supports statistical comparison of oxygenation and perfusion indices across experimental conditions.
- Translational Research: Bridges preclinical findings with clinical imaging and biomarker strategies for malperfusion syndromes.
- Enterprise Reuse: Offers a standardized, reusable model for diverse vascular and tissue-protection research initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in perfusion-targeted research.
- Operational Value: Enhances reproducibility, standardization, and scalability of in vivo malperfusion studies.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust, quantitative endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of vascular and tissue-protection candidates.
Implementation Considerations
- Requires surgical expertise in rodent laparotomy and vascular clamping techniques.
- Demands access to hyperspectral imaging systems and quantitative analytical infrastructure.
- Necessitates cross-team standardization of surgical protocols and imaging readouts.
- Adaptation to other species or organ systems may require protocol optimization.
- Limitations include the need for precise timing and technical consistency to ensure reversibility and reproducibility.
Biopharma FAQs
Why does null hypothesis testing matter for malperfusion target validation?
Null hypothesis testing in this model enables objective evaluation of whether specific interventions or imaging modalities can reliably distinguish between physiological and malperfused states, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit the malperfusion discovery pipeline?
By enabling controlled induction of arterial, venous, and combined malperfusion, the protocol isolates key variables, allowing teams to dissect mechanistic contributions and optimize candidate selection for vascular and tissue-targeted therapies.
What do quantitative dependent variable measurements enable in this model?
Quantitative measurements of oxygenation and perfusion indices via hyperspectral imaging provide objective endpoints for comparing experimental groups, supporting statistical rigor and reproducibility in biomarker and therapeutic validation.
Why are replication requirements critical for cross-functional malperfusion studies?
Replication ensures that observed effects are consistent and reproducible across teams and studies, enabling reliable cross-functional collaboration and confidence in advancing candidates through the R&D pipeline.
What statistical analysis capabilities are required before implementing imaging readouts?
Robust statistical analysis is needed to compare oxygenation and perfusion values across malperfusion states, validate imaging thresholds, and support data-driven decision-making for candidate progression and biomarker qualification.
